Lupin ko FDA se tentative approval mila! COPD drug Revefenacin ke liye gud news

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorVihaan Mehta|Published at:
Lupin ko FDA se tentative approval mila! COPD drug Revefenacin ke liye gud news
Overview

Arre yaaron, Lupin ke liye ek mast khabar hai! Unke COPD drug, Revefenacin Inhalation Solution, ko US FDA se tentative approval mil gaya hai. Isse unka US market mein ek bada segment target ho jayega.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Lupin ke liye ek badi khabar hai! Unke COPD drug, Revefenacin Inhalation Solution, ko US FDA se 'tentative' approval mil gaya hai. Yeh drug essentially un patients ke liye hai jo Chronic Obstructive Pulmonary Disease (COPD) se suffer karte hain.

Abhi yeh approval 'tentative' hai, yaani ki Lupin ko final launch se pehle FDA ki kuch aur requirements poori karni padengi. Lekin yeh ek bahut important step hai!

Ye drug US market mein Mylan ke Yupelri® Inhalation Solution wale segment ko target kar raha hai. Aur Yupelri® ka toh US mein saal ka sale tha lagbhag USD 260.7 million! Toh potential market kafi bada lag raha hai.

Lupin ke liye yeh regulatory step unke respiratory drug portfolio ko US mein strong banane mein madad karega. Competition toh hai hi, kyunki Sun Pharma, Dr. Reddy's, aur Cipla jaise bade players bhi US mein active hain aur aise hi therapeutic areas mein compete karte hain.

Abhi sabki nazar iss baat par rahegi ki Lupin final FDA approval kab secure karta hai aur apne drug ko market mein kaise launch karta hai. Dekhte hain aage kya hota hai!

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.